Scientists are using artificial intelligence to develop nasal antivirals designed to stop viruses such as influenza and COVID-19 before they can enter human cells. The approach marks a shift from treating infections after they take hold to preventing them at the earliest possible stage.
Rather than focusing on vaccines alone, researchers are targeting the moment viruses attempt to fuse with cells or establish themselves in the nasal cavity. That entry point is often where respiratory infections begin.
